Recent developments include financial results announcements, clinical trial progress, regulatory interactions, capital raises, and strategic partnerships.

• Cellectar reported Q4 2025 earnings and provided a corporate update on March 4, 2026 [N1].
• The company’s stock rose following EMA's positive scientific advice on CMA filing for iopofosine I 131 in October 2025 [N2].
• Cellectar reduced losses and expenses in Q2 2025 [N3].
• The CEO purchased 10,000 shares in July 2025 [N4].
• Completed a $6.9 million public offering in July 2025 to advance cancer treatment development [N5][N6].
• Partnered with Nusano for long-term supply of iodine-125 and actinium-225 isotopes to support cancer treatment development in June 2025 [N8].
• Announced a one-for-thirty reverse stock split effective June 24, 2025 [N7].
• Reported promising initial results from CLOVER-2 Phase 1 trial of iopofosine I 131 for pediatric high-grade glioma in June 2025 [N1].

The company has reported promising clinical data for iopofosine I 131, including an 83.6% overall response rate in a Phase 2 study, and has received breakthrough therapy designation. Positive feedback from the EMA's scientific advice procedure supports potential conditional marketing approval filings. Recent capital raises and partnerships for isotope supply support ongoing development. Experienced leadership and a focused pipeline targeting unmet medical needs in oncology provide a foundation for potential future regulatory approvals and commercialization.

Cellectar faces significant regulatory risks as FDA and EMA approvals are uncertain and subject to discretionary review. The company’s existing cash is insufficient to complete planned clinical studies and regulatory submissions, requiring additional funding that may not be available on acceptable terms. Failure to secure funding could lead to operational discontinuation, asset sales, or bankruptcy. Clinical trial outcomes may not meet endpoints, and regulatory authorities may require additional studies, delaying or preventing product approvals. The company operates in a highly competitive and capital-intensive biotech sector with inherent execution risks.

Cellectar's moat is based on its proprietary phospholipid drug conjugate technology platform and its focus on targeted radiotherapeutics for cancer treatment. The company’s lead candidate, iopofosine I 131, has received breakthrough therapy designation and shows promising clinical response rates, which may provide competitive differentiation if regulatory approvals are obtained. Strategic partnerships for isotope supply and experienced management and board members contribute to its operational capabilities. However, as a clinical-stage company, it faces typical biotech risks including regulatory uncertainty and funding dependency.

• Regulatory Approval Risk: FDA, EMA, and other regulatory authorities have substantial discretion and may refuse to file, review, or approve iopofosine I 131 or other product candidates. Additional studies may be required, and approval is not guaranteed [S2].
• Funding Risk: Existing cash and cash equivalents are insufficient to complete regulatory strategy and clinical development. The company depends on raising additional capital, which may not be available or sufficient, potentially leading to operational discontinuation or bankruptcy [S2].
• Clinical Development Risk: Clinical trials may fail to meet safety or efficacy endpoints, or data may be deemed insufficient by regulators, impacting approval prospects and business viability [S2].
• Operational Risk: Failure to execute regulatory strategy or raise funds may require sale of assets, discontinuation of operations, or winding down the company [S2].

• Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments, including iopofosine I 131 and CLR 125 [S1][S2].
• The company plans to submit a New Drug Application (NDA) to the FDA for accelerated approval of iopofosine I 131 for treatment of Waldenström's macroglobulinemia (WM) patients who have received two prior lines of therapy including a BTK inhibitor [S2].
• Cellectar is also engaged in dialogue with the European Medicines Agency (EMA) regarding a possible conditional marketing approval (CMA) submission for iopofosine I 131 [S2][N2].
• The EMA's scientific advice procedure indicated that filing a CMA for iopofosine I 131 as a treatment for post-BTKi refractory WM patients could be acceptable, but this does not guarantee final approval [S2].
• The company has reported an 83.6% overall response rate from the CLOVER WaM Phase 2 study of iopofosine I 131 [N1].
• Cellectar is conducting a Phase 1b dose-finding study for CLR 125 but does not expect existing cash to be sufficient to progress through preliminary data readout, requiring additional funding [S2].
• The company completed a $6.9 million public offering in mid-2025 to advance cancer treatment development [N5][N6].
• Cellectar has partnered with Nusano for long-term supply of iodine-125 and actinium-225 isotopes to support cancer treatment development [N8].
• The company announced a one-for-thirty reverse stock split effective June 24, 2025 [N7].
• As of December 31, 2025, Cellectar had cash and cash equivalents of approximately $13.2 million and current assets of about $14.0 million, with current liabilities of approximately $4.7 million, resulting in a current ratio of 2.96 and a cash ratio of 2.78 [S1].
• The company reported a net loss of $21.8 million and basic and diluted EPS of -$8.35 for the fiscal year ended December 31, 2025 [S1].
• The company’s existing cash and cash equivalents are not sufficient to execute its regulatory strategy, and additional funding is viewed as a prerequisite to NDA submission and confirmatory studies [S2].
• The company’s regulatory strategy faces risks including FDA and EMA discretion, potential refusal to file or approve applications, and possible requirements for additional studies [S2].
• The company’s inability to raise additional funds could lead to adverse outcomes including sale of assets, discontinuation of operations, wind-down, or bankruptcy [S2].
• The Board of Directors includes experienced executives and independent directors with backgrounds in biotechnology, finance, and oncology [S1].
• The CEO, James V. Caruso, has extensive experience in biotechnology and oncology sectors [S1].
• The company has issued inducement warrants and completed warrant exercises to raise capital, with proceeds expected to fund operations into the third quarter of 2026 [S1].
• The company’s audit firm is Deloitte & Touche LLP, with audit fees disclosed for fiscal years 2024 and 2025 [S1].